Spondyloarthritis & psoriatic arthritis
Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the ‘AIRE’ multicentre study
Authors' conclusion
This RWE study showed that ADA and IXE provide similar 12-month joint outcomes, while IXE showed a faster skin response.
Study context
- Population
- Real-world psoriatic arthritis (PsA) population; ADA group mainly axial and nail involvement, ixekizumab (IXE) group mostly biologic disease-modifying antirheumatic drug (bDMARD)-experienced with higher CRP and worse functional status42% ADA
- Participants
- 437 participants
- Exposure
- Adalimumab vs ixekizumab in real-world PsA
- Outcome
- DAPSA and PASI over time, compared by mixed-effects models
- Follow-up
- 12 months
Methodological detailsmulticentre, real-world, mixed-effects models, time-dependent Cox models adjusted for confounders
- Multicentre
- Real-world
- Mixed-effects models
- Time-dependent Cox models adjusted for confounders
Main finding
As reported in the abstract
- Disease Activity in Psoriatic Arthritis (DAPSA) improved in both groups; between-treatment differences in DAPSA pathways over time not significant
- Psoriasis Areas and Severity Index (PASI) improved similarly in both groups
Observational data: associations, not effects.
Further findings
PASI early reduction from baseline · 3 months
- IXE showed a greater early reduction from baseline
DAPSA remission or Minimal Disease Activity (MDA) · 12 months
- Probabilities did not differ by drug
Predictors of DAPSA remission and MDA
- Associated with male sex, absence of nail psoriasis, higher PASI, fewer prior bDMARDs and better functional status
Original publication
Comparative effectiveness and predictors of remission between adalimumab and ixekizumab in patients with psoriatic arthritis: findings from the ‘AIRE’ multicentre study. RMD Open. Published 24 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →